Gujarat Kidney And Super Speciality Limited has informed the Exchange about reasons for Delayed of unaudited Financial Results of September 30, 2025
GKSL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Gujarat Kidney and Super Speciality Limited, which got listed on the exchanges on December 30, 2025, disclosed that it delayed uploading its Q2 FY26 (September 30, 2025) financial results because it did not receive the email intimation from the exchange due to a technical issue. The company called this a one-time lapse as a newly listed entity and confirmed that subsequent quarterly filings have been on time. For Q2 FY26 on a standalone basis, revenue from operations stood at ₹964.26 lakhs (down from ₹1,144.99 lakhs in Q1 FY26) with a profit after tax of ₹230.12 lakhs and an EPS of ₹0.45. For the half year ended September 30, 2025, standalone PAT was ₹620.10 lakhs (EPS ₹1.22), while consolidated revenue reached ₹2,818.90 lakhs with a PAT of ₹827.96 lakhs (EPS ₹1.47). The auditor (Y.M. Shah & Co.) issued an unmodified limited review report on both standalone and consolidated results.
The delay itself is a minor compliance hiccup attributed to a technical email issue and is unlikely to have a lasting impact given that subsequent filings are on track. Investors will focus more on the actual numbers, which show healthy half-yearly profitability and revenue growth on a consolidated basis, supported by subsidiary hospitals.